136 related articles for article (PubMed ID: 12373425)
1. Comparison of the discriminative and neuroendocrine effects of centrally penetrating kappa-opioid agonists in rhesus monkeys.
Butelman ER; Ball JW; Kreek MJ
Psychopharmacology (Berl); 2002 Oct; 164(1):115-20. PubMed ID: 12373425
[TBL] [Abstract][Full Text] [Related]
2. Peripheral selectivity and apparent efficacy of dynorphins: comparison to non-peptidic kappa-opioid agonists in rhesus monkeys.
Butelman ER; Ball JW; Kreek MJ
Psychoneuroendocrinology; 2004 Apr; 29(3):307-26. PubMed ID: 14644063
[TBL] [Abstract][Full Text] [Related]
3. Opioid interactions in rhesus monkeys: effects of delta + mu and delta + kappa agonists on schedule-controlled responding and thermal nociception.
Stevenson GW; Folk JE; Linsenmayer DC; Rice KC; Negus SS
J Pharmacol Exp Ther; 2003 Dec; 307(3):1054-64. PubMed ID: 14557380
[TBL] [Abstract][Full Text] [Related]
4. kappa-Opioid receptor agonist-induced prolactin release in primates is blocked by dopamine D(2)-like receptor agonists.
Butelman ER; Kreek MJ
Eur J Pharmacol; 2001 Jul; 423(2-3):243-9. PubMed ID: 11448491
[TBL] [Abstract][Full Text] [Related]
5. Kappa opioid antagonist effects of the novel kappa antagonist 5'-guanidinonaltrindole (GNTI) in an assay of schedule-controlled behavior in rhesus monkeys.
Negus SS; Mello NK; Linsenmayer DC; Jones RM; Portoghese PS
Psychopharmacology (Berl); 2002 Oct; 163(3-4):412-9. PubMed ID: 12373442
[TBL] [Abstract][Full Text] [Related]
6. GR89,696: a potent kappa-opioid agonist with subtype selectivity in rhesus monkeys.
Butelman ER; Ko MC; Traynor JR; Vivian JA; Kreek MJ; Woods JH
J Pharmacol Exp Ther; 2001 Sep; 298(3):1049-59. PubMed ID: 11504802
[TBL] [Abstract][Full Text] [Related]
7. Micro/kappa opioid interactions in rhesus monkeys: implications for analgesia and abuse liability.
Negus SS; Schrode K; Stevenson GW
Exp Clin Psychopharmacol; 2008 Oct; 16(5):386-99. PubMed ID: 18837635
[TBL] [Abstract][Full Text] [Related]
8. The plant-derived hallucinogen, salvinorin A, produces kappa-opioid agonist-like discriminative effects in rhesus monkeys.
Butelman ER; Harris TJ; Kreek MJ
Psychopharmacology (Berl); 2004 Mar; 172(2):220-4. PubMed ID: 14586540
[TBL] [Abstract][Full Text] [Related]
9. Effects of salvinorin A, a kappa-opioid hallucinogen, on a neuroendocrine biomarker assay in nonhuman primates with high kappa-receptor homology to humans.
Butelman ER; Mandau M; Tidgewell K; Prisinzano TE; Yuferov V; Kreek MJ
J Pharmacol Exp Ther; 2007 Jan; 320(1):300-6. PubMed ID: 17060493
[TBL] [Abstract][Full Text] [Related]
10. Discriminative stimulus effects of the nonpeptidic delta-opioid agonist SNC80 in rhesus monkeys.
Brandt MR; Negus SS; Mello NK; Furness MS; Zhang X; Rice KC
J Pharmacol Exp Ther; 1999 Sep; 290(3):1157-64. PubMed ID: 10454490
[TBL] [Abstract][Full Text] [Related]
11. Enadoline discrimination in squirrel monkeys: effects of opioid agonists and antagonists.
Carey GJ; Bergman J
J Pharmacol Exp Ther; 2001 Apr; 297(1):215-23. PubMed ID: 11259547
[TBL] [Abstract][Full Text] [Related]
12. Interactions between cannabinoid receptor agonists and mu opioid receptor agonists in rhesus monkeys discriminating fentanyl.
Maguire DR; France CP
Eur J Pharmacol; 2016 Aug; 784():199-206. PubMed ID: 27184925
[TBL] [Abstract][Full Text] [Related]
13. Discriminative stimulus effects of mu and kappa opioids in the pigeon: analysis of the effects of full and partial mu and kappa agonists.
Picker MJ; Dykstra LA
J Pharmacol Exp Ther; 1989 May; 249(2):557-66. PubMed ID: 2566680
[TBL] [Abstract][Full Text] [Related]
14. Discriminative stimulus effects of opioids in pigeons trained to discriminate fentanyl, bremazocine and water: evidence of pharmacological selectivity.
Picker MJ; Cook CD
Behav Pharmacol; 1997 Jun; 8(2-3):160-73. PubMed ID: 9833011
[TBL] [Abstract][Full Text] [Related]
15. Antinociceptive and response rate-altering effects of kappa opioid agonists, spiradoline, enadoline and U69,593, alone and in combination with opioid antagonists in squirrel monkeys.
Pitts RC; Dykstra LA
J Pharmacol Exp Ther; 1994 Dec; 271(3):1501-8. PubMed ID: 7996463
[TBL] [Abstract][Full Text] [Related]
16. Effects of E-2078, a stable dynorphin A(1-8) analog, on sedation and serum prolactin levels in rhesus monkeys.
Butelman ER; Harris TJ; Kreek MJ
Psychopharmacology (Berl); 1999 Nov; 147(1):73-80. PubMed ID: 10591871
[TBL] [Abstract][Full Text] [Related]
17. Discriminative stimulus effects of butorphanol: influence of training dose on the substitution patterns produced by Mu, Kappa and Delta opioid agonists.
Picker MJ; Benyas S; Horwitz JA; Thompson K; Mathewson C; Smith MA
J Pharmacol Exp Ther; 1996 Dec; 279(3):1130-41. PubMed ID: 8968334
[TBL] [Abstract][Full Text] [Related]
18. The effects of spiradoline (U-62066E), a kappa-opioid receptor agonist, on neuroendocrine function in man.
Ur E; Wright DM; Bouloux PM; Grossman A
Br J Pharmacol; 1997 Mar; 120(5):781-4. PubMed ID: 9138682
[TBL] [Abstract][Full Text] [Related]
19. The discriminative effects of the kappa-opioid hallucinogen salvinorin A in nonhuman primates: dissociation from classic hallucinogen effects.
Butelman ER; Rus S; Prisinzano TE; Kreek MJ
Psychopharmacology (Berl); 2010 Jun; 210(2):253-62. PubMed ID: 20084367
[TBL] [Abstract][Full Text] [Related]
20. Age-related differences in sensitivity to the antinociceptive effects of kappa opioids in adult male rats.
Smith MA; French AM
Psychopharmacology (Berl); 2002 Jul; 162(3):255-64. PubMed ID: 12122483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
